Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Feature|Articles|March 3, 2026
Expert Zahra Mahmoudjafari on Turning Innovation Into Implementation in Cell and Gene Therapy Programs
Fact checked by: Kirsty Mackay
Launching sustainable, effective CGT programs requires a road map for strategy, operations, access, finance, quality, and pharmacy.
Advertisement
Advertisement
Cell and gene therapies (CGTs), including chimeric antigen receptor (CAR) T-cell therapies, tumor-infiltrating lymphocytes, and gene therapies, represent one of the most innovative and disruptive advances in modern medicine. They offer potentially curative, one-time treatments that fundamentally redefine how clinicians approach serious and previously incurable diseases.
Related to this article
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Advertisement
Advertisement